Enzon Pharmaceuticals, Inc. (ENZN) said Thursday it filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission related to its plan to spin-off its biotechnology business to Enzon's shareholders.
Earlier in May 2008, Enzon announced its plan to spin-off its biotechnology business, named Evivrus, Inc., to create a separate, publicly-traded, highly-focused biotechnology company.
Evivrus will focus on the discovery and development of important medicines for patients with cancer and other life-threatening conditions utilizing cutting-edge technologies, including PEGylation Customized Linker Technology and Locked Nucleic Acid technology.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.